GERNGERON CORPvs its industry peers
A metric-by-metric comparison of GERON CORP against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERNThis | $832M#8 | — | 3.8x#10 | 3510.6x#10 | -60.2%#9 | 52.2%#5 | -28938.8%#10 | -38.2%#12 | -24.8%#6 | — | 3.2%#12 | — |
| WVE | $889M#1 | — | 2.0x#3 | 20.8x#8 | -60.5%#10 | -110.7%#16 | -504.1%#8 | -45.1%#14 | — | — | -33.9%#14 | — |
| TBPH | $884M#2 | 16.4x#3 | 3.1x#6 | 8.2x#7 | 66.9%#2 | 287.7%#2 | -3.4%#4 | 36.6%#3 | — | — | 22.8%#11 | — |
| FTH | $879M#3 | — | 5.1x#12 | — | — | 30.1%#7 | — | -12.2%#7 | -15.2%#4 | — | 270.2%#3 | — |
| IMMX | $853M#4 | — | 3.7x#9 | — | — | -36.0%#11 | — | -12.8%#8 | — | — | 496.5%#2 | — |
| OLMA | $851M#5 | — | 2.0x#4 | — | — | -25.5%#10 | — | -37.7%#11 | — | — | 23.3%#10 | — |
| ARDX | $847M#6 | — | 5.7x#13 | 2.1x#2 | 22.1%#5 | -59.0%#15 | -10.1%#5 | -41.6%#13 | -52.3%#7 | — | -47.1%#16 | — |
| CYRX | $836M#7 | — | 1.7x#1 | 4.7x#4 | 12.4%#6 | 168.2%#4 | -20.9%#6 | 16.0%#5 | -16.5%#5 | 4#1 | 83.2%#7 | — |
| RIGL | $831M#9 | 2.6x#1 | 2.0x#2 | 2.8x#3 | 64.1%#3 | 1999.1%#1 | 42.6%#1 | 86.3%#1 | 30.6%#2 | — | 27.0%#9 | — |
| CLYM | $810M#10 | — | 3.4x#8 | — | — | 19.0%#8 | — | -25.0%#9 | — | — | 600.2%#1 | — |
| ACRS | $784M#11 | — | 6.3x#14 | 100.2x#9 | -58.2%#8 | 50.8%#6 | -975.9%#9 | -52.1%#15 | -65.8%#8 | 3#3 | 190.2%#5 | — |
| DSGN | $783M#12 | — | 3.9x#11 | — | — | -40.7%#13 | — | -34.6%#10 | — | — | 114.3%#6 | — |
| GYRE | $749M#13 | — | 6.9x#15 | 6.4x#5 | 10.2%#7 | -44.8%#14 | 9.9%#3 | 9.2%#6 | 12.0%#3 | 3#3 | -9.2%#13 | 6.0%#1 |
| COLL | $723M#14 | 17.5x#4 | 2.3x#5 | 0.9x#1 | 23.6%#4 | -8.7%#9 | 23.0%#2 | 20.2%#4 | 62.0%#1 | 4#1 | -37.7%#15 | — |
| NVCT | $712M#15 | — | 78.4x#16 | — | — | -39.2%#12 | — | -291.1%#16 | — | — | 252.4%#4 | — |
| ZVRA | $701M#16 | 12.7x#2 | 3.2x#7 | 6.6x#6 | 350.9%#1 | 178.9%#3 | -59.1%#7 | 38.2%#2 | — | — | 62.6%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice